Literature DB >> 9295032

Interleukin-12 acts as an adjuvant for humoral immunity through interferon-gamma-dependent and -independent mechanisms.

D W Metzger1, R M McNutt, J T Collins, J M Buchanan, V H Van Cleave, W A Dunnick.   

Abstract

Interleukin-12 (IL-12) is a pivotal cytokine that has dramatic effects on cell-mediated immunity. It is now becoming increasingly recognized that IL-12 also strongly controls humoral immunity. We have investigated the mechanism by which IL-12 induces alterations in antibody isotype expression by determining the influence of IL-12 on in vitro immunoglobulin (Ig) production in polyclonally activated murine spleen cell cultures. Cells exposed to IL-12 plus lipopolysaccharide or anti-CD40 monoclonal antibody showed dramatically elevated IgG2a and suppressed IgG1 production compared to cells cultured in the absence of IL-12. IL-12 treatment of spleen cell cultures induced expression of gamma2a germ-line transcripts, consistent with initiation of switch recombination to IgG2a. In addition, exposure of limiting dilution cultures to IL-12 increased IgG2a+ cell precursor frequency. All of the above results were dependent on interferon-gamma (IFN-gamma). However, in the absence of IFN-gamma, IL-12 still had significant effects on Ig secretion. Specifically, IL-12 enhanced IgG1 and IgG2b anti-DNP antibody levels in mice containing specific disruptions in the IFN-gamma gene. Our results suggest that IL-12 induces T helper type 1 and natural killer cells to secrete large amounts of IFN-gamma which then causes B cells to switch to IgG2a and IgG3 production. In addition, IL-12 has direct or indirect effects on B cells that are independent of IFN-gamma. The IFN-gamma-independent effects may include enhancement of Ig expression by post-switched cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9295032     DOI: 10.1002/eji.1830270820

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  21 in total

Review 1.  Interleukin 12 and innate molecules for enhanced mucosal immunity.

Authors:  P N Boyaka; J W Lillard; J McGhee
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

2.  Coadministration of interleukin 12 expression vector with antigen 2 cDNA enhances induction of protective immunity against Coccidioides immitis.

Authors:  C Jiang; D M Magee; R A Cox
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

3.  Interleukin-12 as an adjuvant for an antischistosome vaccine consisting of adult worm antigens: protection of rats from cercarial challenge.

Authors:  R D Bungiro; M Goldberg; P K Suri; P M Knopf
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

4.  Plasma IL-12 levels are suppressed in vivo by stress and surgery through endogenous release of glucocorticoids and prostaglandins but not catecholamines or opioids.

Authors:  Lee Shaashua; Ella Rosenne; Elad Neeman; Liat Sorski; Luba Sominsky; Pini Matzner; Gayle G Page; Shamgar Ben-Eliyahu
Journal:  Psychoneuroendocrinology       Date:  2014-01-07       Impact factor: 4.905

5.  Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection.

Authors:  B P Arulanandam; J M Lynch; D E Briles; S Hollingshead; D W Metzger
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

Review 6.  Interleukin-12 as an adjuvant for induction of protective antibody responses.

Authors:  Dennis W Metzger
Journal:  Cytokine       Date:  2010-07-22       Impact factor: 3.861

7.  Immunization of mice with phosphatidylcholine drastically reduces the parasitaemia of subsequent Plasmodium chabaudi chabaudi blood-stage infections.

Authors:  G Bordmann; W Rudin; N Favre
Journal:  Immunology       Date:  1998-05       Impact factor: 7.397

8.  Early control of Mycobacterium tuberculosis infection requires il12rb1 expression by rag1-dependent lineages.

Authors:  Halli E Miller; Richard T Robinson
Journal:  Infect Immun       Date:  2012-08-20       Impact factor: 3.441

9.  Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12.

Authors:  Joyce M Lynch; David E Briles; Dennis W Metzger
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

10.  Pathways for potentiation of immunogenicity during adjuvant-assisted immunizations with Plasmodium falciparum major merozoite surface protein 1.

Authors:  G S Hui; C N Hashimoto
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.